Literature DB >> 33846276

2020 Year in Review: Pharmacologic Treatments for COVID-19.

Jessica L Saunders1, Michael D Davis2.   

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 infection, has led to a pandemic of acute respiratory illness. Pharmacologic treatments for COVID-19 have included treatments that target infection prevention, prevention of viral replication, reduce inflammation, and manage symptoms of respiratory failure caused by the disease. This is a review of key pharmacologic treatments for COVID-19 based on peer-reviewed articles from 2020.
Copyright © 2021 by Daedalus Enterprises.

Entities:  

Keywords:  COVID-19; Optate; REGN-CoV-2; SARS-CoV-2; airway pH; dexamethasone; remdesivir

Mesh：

Substances：

Year:  2021        PMID： 33846276      PMCID： PMC8984919          DOI： 10.4187/respcare.09153

Source DB:  PubMed          Journal:  Respir Care        ISSN： 0020-1324            Impact factor:   2.258


  20 in total

1.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.

Authors:  Timothy P Sheahan; Amy C Sims; Rachel L Graham; Vineet D Menachery; Lisa E Gralinski; James B Case; Sarah R Leist; Krzysztof Pyrc; Joy Y Feng; Iva Trantcheva; Roy Bannister; Yeojin Park; Darius Babusis; Michael O Clarke; Richard L Mackman; Jamie E Spahn; Christopher A Palmiotti; Dustin Siegel; Adrian S Ray; Tomas Cihlar; Robert Jordan; Mark R Denison; Ralph S Baric
Journal:  Sci Transl Med       Date:  2017-06-28       Impact factor: 17.956

2.  Safety of an alkalinizing buffer designed for inhaled medications in humans.

Authors:  Michael D Davis; Brian K Walsh; Scott T Dwyer; Casey Combs; Nico Vehse; Alix Paget-Brown; Thomas Pajewski; John F Hunt
Journal:  Respir Care       Date:  2012-12-18       Impact factor: 2.258

3.  Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update.

Authors:  Waleed Alhazzani; Laura Evans; Fayez Alshamsi; Morten Hylander Møller; Marlies Ostermann; Hallie C Prescott; Yaseen M Arabi; Mark Loeb; Michelle Ng Gong; Eddy Fan; Simon Oczkowski; Mitchell M Levy; Lennie Derde; Amy Dzierba; Bin Du; Flavia Machado; Hannah Wunsch; Mark Crowther; Maurizio Cecconi; Younsuck Koh; Lisa Burry; Daniel S Chertow; Wojciech Szczeklik; Emilie Belley-Cote; Massimiliano Greco; Malgorzata Bala; Ryan Zarychanski; Jozef Kesecioglu; Allison McGeer; Leonard Mermel; Manoj J Mammen; Sheila Nainan Myatra; Amy Arrington; Ruth Kleinpell; Giuseppe Citerio; Kimberley Lewis; Elizabeth Bridges; Ziad A Memish; Naomi Hammond; Frederick G Hayden; Muhammed Alshahrani; Zainab Al Duhailib; Greg S Martin; Lewis J Kaplan; Craig M Coopersmith; Massimo Antonelli; Andrew Rhodes
Journal:  Crit Care Med       Date:  2021-03-01       Impact factor: 7.598

4.  GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.

Authors:  Michael K Lo; Robert Jordan; Aaron Arvey; Jawahar Sudhamsu; Punya Shrivastava-Ranjan; Anne L Hotard; Mike Flint; Laura K McMullan; Dustin Siegel; Michael O Clarke; Richard L Mackman; Hon C Hui; Michel Perron; Adrian S Ray; Tomas Cihlar; Stuart T Nichol; Christina F Spiropoulou
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

5.  Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.

Authors:  Maria L Agostini; Erica L Andres; Amy C Sims; Rachel L Graham; Timothy P Sheahan; Xiaotao Lu; Everett Clinton Smith; James Brett Case; Joy Y Feng; Robert Jordan; Adrian S Ray; Tomas Cihlar; Dustin Siegel; Richard L Mackman; Michael O Clarke; Ralph S Baric; Mark R Denison
Journal:  mBio       Date:  2018-03-06       Impact factor: 7.867

6.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

7.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.

Authors:  David M Weinreich; Sumathi Sivapalasingam; Thomas Norton; Shazia Ali; Haitao Gao; Rafia Bhore; Bret J Musser; Yuhwen Soo; Diana Rofail; Joseph Im; Christina Perry; Cynthia Pan; Romana Hosain; Adnan Mahmood; John D Davis; Kenneth C Turner; Andrea T Hooper; Jennifer D Hamilton; Alina Baum; Christos A Kyratsous; Yunji Kim; Amanda Cook; Wendy Kampman; Anita Kohli; Yessica Sachdeva; Ximena Graber; Bari Kowal; Thomas DiCioccio; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D Yancopoulos
Journal:  N Engl J Med       Date:  2020-12-17       Impact factor: 91.245

8.  Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.

Authors:  Alina Baum; Benjamin O Fulton; Elzbieta Wloga; Richard Copin; Kristen E Pascal; Vincenzo Russo; Stephanie Giordano; Kathryn Lanza; Nicole Negron; Min Ni; Yi Wei; Gurinder S Atwal; Andrew J Murphy; Neil Stahl; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

9.  An interactive web-based dashboard to track COVID-19 in real time.

Authors:  Ensheng Dong; Hongru Du; Lauren Gardner
Journal:  Lancet Infect Dis       Date:  2020-02-19       Impact factor: 25.071

10.  Elevated FiO2 increases SARS-CoV-2 co-receptor expression in respiratory tract epithelium.

Authors:  Despoina Myti; Miša Gunjak; Francisco Casado; Solmaz Khaghani Raziabad; Claudio Nardiello; István Vadász; Susanne Herold; Gloria Pryhuber; Werner Seeger; Rory E Morty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-09-02       Impact factor: 6.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.